Clinical Research Directory

Inclusion Criteria: * Having the ability to voluntarily give their signed informed consent. * Clinically healthy subjects. * Being able to and willing to comply with scheduled visits, treatment plan, and other study procedures. * Age ≥ 18 years. * No history of contact lens wear * Women of childbearing potential who have not undergone Bilateral Tubal Occlusion (BTO \[Tubal Ligation\]), hysterectomy, or bilateral oophorectomy must ensure continuation (initiated ≥ 30 days prior to signing the ied consent form \[ICF\]) of the use of a hormonal contraceptive method or intrauterine device (IUD) during the study period. * Having vital signs within normal parameters. * Best corrected visual acuity (BCVA) of 20/30 or better in both eyes. * Having an intraocular pressure ≥ 10 and ≤ 21 mmHg. Exclusion Criteria: * History of hypersensitivity to any of the components of the drugs under investigation. * Use of ophthalmic medications from any pharmacological group. * Use of medications by any other route of administration. * In the case of women: being pregnant, breastfeeding, or planning to become pregnant within the study period. * Having participated in any clinical research study 30 days prior to inclusion in this study. * Having previously participated in this same study. * History of any chronic-degenerative disease, including Diabetes Mellitus or Systemic Arterial Hypertension. * Diagnosis of glaucoma or ocular hypertension. * Known diagnosis of liver or heart disease. * Presenting active inflammatory or infectious disease at the time of entry into the study. * Presenting unresolved lesions or traumas at the time of entry into the study. * Having been subjected to non-ophthalmological surgical procedures in the last 3 months. * Being or having an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is an employee of the research site or the sponsor, and who directly participates in this study. Elimination Criteria * Withdrawal of their consent to participate in the study (informed consent form). * Occurrence of a serious adverse event, whether related or not to the interventions, that in the opinion of the principal investigator (PI) and/or the sponsor, could affect the patient's fitness to safely continue with the study procedures. * Non-tolerability or hypersensitivity to any of the compounds used during the tests -(fluorescein, tetracaine). * Non-tolerability or hypersensitivity to any of the drugs under investigation. * Adherence \< 80% determined by the subject's diary and corroborated by the final weight of the research products (RP) compared to the initial weight.